| INSULIN ZINC SUSPENSION (LENTE) (in'su-lyn)
 Humulin L, Novolin L
 Classifications: hormone; antidiabetic agent; insulin intermediate-acting;  Therapeutic: antidiabetic; insulin intermediate-acting
 Prototype: Insulin injection
 Pregnancy Category: B
 
 | 
 
 
 
 Availability
 
 100 units/mL
 
 Action
 
 Intermediate-acting human insulin created by adding zinc ions to human regular insulin. It lowers blood glucose levels by 
 increasing peripheral glucose uptake, especially by skeletal muscle and fat tissue, and by inhibiting the liver from changing 
 glycogen to glucose. It is not the ideal basal insulin since its absorption is variable. 
 
 
 Therapeutic Effect
 
 It lowers glucose level over a longer period of time than regular human insulin.
 
 Uses
 
 Hyperglycemia in diabetic patients allergic to other preparations of insulin. Also for patients with evidence of thrombotic 
 phenomena in which protamine may be a factor. 
 
 
 Contraindications
 
 During episodes of hypoglycemia or in patients sensitive to any ingredient in the formulation; insulin pump; intravenous 
 administration; hyperosmolar hyperglycemic state; diabetic ketoacidosis. 
 
 
 Cautious Use
 
 In insulin resistant patients, hyperthyroidism or hypothyroidism; lactation, older adults, pregnancy (category B), renal 
 or hepatic impairment; children. 
 
 
 Route & Dosage
 
  
  
 | Diabetes Mellitus Adult: IM/SC Individualized doses (see INSULIN INJECTION, REGULAR)
 
 | 
 
 
 
 
Administration
Subcutaneous/Intramuscular 
 - Give insulin zinc suspensions 30 min before breakfast. Some patients require another injection 30 min before supper time 
 or at bedtime. 
 
- Note: Zinc insulin preparation (Lente) is compatible with regular insulin.
- Ensure complete dispersion by mixing thoroughly by gently rotating the vial between the palms and by inverting it end-to-end 
 several times. Do not shake. 
 
- Note: Time of action of insulin zinc (Lente) approximates that of isophane insulin suspension (NPH) allowing patients usually 
 to be transferred directly to the latter on a unit-for-unit basis. 
 
- Store unopened vial at 2°8° C (36°46° F). Avoid freezing and exposure to extremes in temperature 
 or to direct sunlight. 
 
Adverse Effects (≥1%)
See 
INSULIN INJECTION, REGULAR. 
 
Interactions
See 
INSULIN INJECTION. 
 
Pharmacokinetics
Onset: 12 h. 
Peak: 812 h. 
Duration: 1824 h. 
Metabolism: In liver and kidney. 
Elimination: <2% excreted unchanged in urine. 
Half-Life: Up to 13 h. 
 
Nursing Implications
 
 (see INSULIN INJECTION, REGULAR) 
 
 
 Patient & Family Education
 
  
 - Be alert for S&S of hypoglycemia (see Appendix F); most apt to occur between mid-afternoon and dinner time (an early symptom 
 may be a sense of extreme fatigue). Immediately take soluble carbohydrate (e.g., orange juice, honey). If the time between 
 the midday and evening meal is prolonged, an afternoon snack may be needed. 
 
- Do not overlook possibility of nocturnal hypoglycemia, especially during dose adjustment. Signs include restlessness or 
 profuse sweating during sleep.